|Bid||80.01 x 800|
|Ask||80.03 x 1100|
|Day's Range||75.82 - 81.00|
|52 Week Range||33.50 - 112.22|
|Beta (3Y Monthly)||1.06|
|PE Ratio (TTM)||454.83|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
eHealth (EHTH) delivered earnings and revenue surprises of 28.33% and 29.29%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
EHealth (EHTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marsh & McLennan's (MMC) subsidiary collaborates with Xevant to offer a strategic optimization solution for employer-funded pharmacy benefit plans.
Marsh & McLennan (MMC) reaches an agreement with Construction Risk Partners, according to which the latter will buy the company's stock from JLT.
Banking on strategic acquisitions and financial flexibility, Marsh & McLennan (MMC) holds enough potential to reap benefits for investors.